Abstract:Background: Interleukin 25 (IL-25) is involved in the initiation of T helper cell (Th)2-mediated immunopathologies. In this study, we investigated the expression of IL-25 in inflammatory bowel disease (IBD) and its role in the induction of CD4(+) T-cell differentiation.Methods: Expression of IL-25 in inflamed mucosa of patients with IBD was determined by quantitative real-time polymerase chain reaction, immunohistochemistry, and enzyme-linked immunosorbent assay. The correlation of IL-25 expression with endoscopic disease activities and C-reactive protein was evaluated. Peripheral blood and lamina propria CD4(+) T cells were stimulated with anti-CD3 and anti-CD28 monoclonal antibodies in the presence of IL-25. Transcription factors and cytokines were determined with real-time polymerase chain reaction, flow cytometry, and enzyme-linked immunosorbent assay.Results: IL-25 was significantly decreased in the sera and inflamed mucosa of patients with active IBD compared with controls. It was upregulated in the sera of patients with Crohn's disease after treatment with infliximab. The levels of IL-25 in inflamed mucosa and sera were inversely correlated with endoscopic disease activities and C-reactive protein, respectively, in IBD. IL-25 could markedly inhibit IBD CD4(+) T cells to produce tumor necrosis factor, interferon gamma, and IL-17A but promote IL-10 secretion. It suppressed the differentiation of IBD CD4(+) T cells into Th1 and Th17 cells but did not interfere with Th2 cell differentiation. Importantly, blockade of IL-10 secretion by IBD CD4+ T cells markedly attenuated the inhibitory role of IL-25 in modulating both Th1 and Th17 immune responses.Conclusions: IL-25 is markedly decreased in IBD and inhibits IBD CD4(+) T-cell activation and differentiation into Th1/Th17 cells in an IL-10-dependent manner, suggesting that it may be a potential therapeutic agent for IBD. (Inflamm Bowel Dis 2013;19:720-728)

Could IL-25 be a potential therapeutic target for intestinal inflammatory diseases?

Interleukin 25 and its biological features and function in intestinal diseases

IL-25 Downregulates Th1/Th17 Immune Response in an IL-10–Dependent Manner in Inflammatory Bowel Disease

The Expression of Interleukin-25 in Patients with Inflammatory Bowel Disease and Its Clinical Significance

The Potential Roles of Interleukin-25 in Infectious Diseases

Role of IL-22 in Intestinal Microenvironment and Potential Targeted Therapy Through Diet

Significance of interleukin-27 expression in the intestinal mucosa of patients with inflammatory bowel disease

IL-25 promotes the function of CD4+CD25+ T regulatory cells and prolongs skin-graft survival in murine models (IRC5P.620)

The role of IL-19, IL-24, IL-21 and IL-33 in intestinal mucosa of inflammatory bowel disease: A narrative review

The Role of Interleukin-17A in Colorectal Tumorigenesis

IL-17RA in intestinal inflammation: structure, signaling, function, and clinical application.

After Interleukin-12P40, Are Interleukin-23 and Interleukin-17 the Next Therapeutic Targets for Inflammatory Bowel Disease?

Potential Role of Th17 Cells in the Pathogenesis of Inflammatory Bowel Disease.

Microbiota-specific Th17 Cells: Yin and Yang in Regulation of Inflammatory Bowel Disease.

Genetic Deletion of Il-25 (Il-17E) Confers Resistance to Dextran Sulfate Sodium-Induced Colitis in Mice

Interleukin (IL)‐25: Pleiotropic Roles in Asthma

Dual Immune Functions of IL-33 in Inflammatory Bowel Disease.

Role of Interleukin-22 in Inflammatory Bowel Disease.

IL-25 Ameliorates Acute Cholestatic Liver Injury Via Promoting Hepatic Bile Acid Secretion.

Critical Role of IL-25 in Nematode Infection-Induced Alterations in Intestinal Function.

A Deep View of the Biological Property of Interleukin-33 and Its Dysfunction in the Gut